Electromed, Inc. (ELMD) Upgraded to Hold at Zacks Investment Research
Electromed, Inc. (NYSEMKT:ELMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “
Separately, TheStreet upgraded shares of Electromed from a “hold” rating to a “buy” rating in a research note on Friday, September 16th.
Electromed (NYSEMKT:ELMD) traded down 3.88% during trading on Thursday, hitting $4.21. 88,119 shares of the stock traded hands. The company has a market cap of $34.59 million, a P/E ratio of 16.91 and a beta of 0.89. Electromed has a 52-week low of $1.55 and a 52-week high of $6.26. The firm has a 50-day moving average price of $4.25 and a 200 day moving average price of $4.36.
Electromed (NYSEMKT:ELMD) last announced its quarterly earnings results on Tuesday, November 8th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by $0.01. The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.90 million. On average, equities analysts expect that Electromed will post $0.13 EPS for the current year.
In other Electromed news, Director William Eckles purchased 20,000 shares of Electromed stock in a transaction dated Thursday, November 10th. The stock was purchased at an average price of $3.61 per share, with a total value of $72,200.00. Following the transaction, the director now directly owns 13,072 shares of the company’s stock, valued at $47,189.92. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Several large investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management Inc. raised its stake in Electromed by 800.0% in the second quarter. Bridgeway Capital Management Inc. now owns 90,000 shares of the company’s stock valued at $347,000 after buying an additional 80,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Electromed by 12.3% in the second quarter. Vanguard Group Inc. now owns 81,929 shares of the company’s stock valued at $316,000 after buying an additional 8,997 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Electromed by 121.3% in the second quarter. Dimensional Fund Advisors LP now owns 81,724 shares of the company’s stock valued at $315,000 after buying an additional 44,795 shares in the last quarter. KCG Holdings Inc. purchased a new stake in Electromed during the third quarter valued at about $343,000. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in Electromed during the third quarter valued at about $323,000.
COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/24/electromed-inc-elmd-upgraded-to-hold-at-zacks-investment-research.html.
Electromed, Inc develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company’s products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others.
Receive News & Stock Ratings for Electromed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed Inc. and related stocks with our FREE daily email newsletter.